spacer
home > > winter 2003 > central laboratories and the importance of an effective quality system
PUBLICATIONS


Central Laboratories and the Importance of an Effective Quality System

Central laboratories play a significant role in the clinical trials process by providing drug development companies with clean, combinable laboratory data, which can be analysed and reported in a timely and cost-effective manner, and which can undergo global regulatory review. Due to the critical nature of the data being generated, it is essential that data are accurate, reliable and reproducible.

So, how can a central laboratory assure its clients of the quality of the data being generated in its operation? The answer lies in the question: the laboratory must establish a quality assurance system. Establishing a quality system involves the implementation of a series of processes and procedures that standardise operations. For a quality system to be credible, it must be examined by an independent external party that is recognised as being competent in the assessment of such a system. These external parties will investigate the laboratory's compliance to a recognised quality standard or guideline and make a recommendation for registration.

There are many different quality standards and guidelines in existence that are recognised in industry. For central laboratories, some quality standards are compulsory depending on the location of operations, whilst other standards are optional and may be adopted by laboratories wishing to enhance their reputation for quality. All central laboratories based in the US are obliged to meet clinical laboratory improvement amendment (CLIA) and state requirements. Additionally, US laboratories, as well as any medical laboratory that handles patient samples which originate in the US, can choose to comply with the requirements of the College of American Pathologists (CAP). In Europe, Asia and Australasia, laboratories will typically aim to comply with the standards published by the International Organization for Standardization (ISO), or with good laboratory practice (GLP) requirements.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Clare O'Sullivan, Laboratory Manager at ICON Laboratories

Clare O'Sullivan is the Laboratory Manager at ICON Laboratories, Europe. She holds a BSc (Hons) and a Masters degree in Microbiology from the National University of Ireland, Cork. Prior to becoming Laboratory Manager, Clare worked as QA Manager for over four years in ICON Laboratories and Tibotec-Virco Ireland, now a division of Johnson and Johnson. During her career as QA Manager she gained experience in the implementation and maintenance of quality systems compliant with ISO 17025, CAP, EN45001, EN45004 and CLIA regulations in both European and US-based facilities.

spacer
Clare O'Sullivan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ATMPS and Ori Biotech Collaborate on an Integrated Digital Platform for Cell and Gene Therapy Developers

London, UK and Woodcliff Lake, NJ, US, April 14, 2021 – ATMPS Ltd, a leader in blockchain-based “vein to vein” cell orchestration platforms for advanced therapies, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing platforms, today announce a global collaboration to create seamless integration between their respective data platforms to support the development of Advanced Therapies.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement